|
Name: Perampanel
Type: Anticonvulsant
AKA: ['Fycompa', '[2-(2-oxo-l-phenyl-5-pyridin-2-yl-l', '2-dihydropyridin-3-yl) benzonitrile ]']
|
|
II. Natural Derivative
Synthetic substance, no natural derivative
 |
|
III. Chemical Profile (IUPAC name)
|
|
IV. History
Perampanel, an anticonvulsant medication, was developed in the early 2010s. It is used for the treatment of epilepsy and seizures. Perampanel's development reflects ongoing research into effective treatments for neurological disorders. Its introduction to the market has provided a new option for managing epilepsy, with a focus on efficacy and safety.
|
|
V. Legal Information
Perampanel, an anticonvulsant used to treat epilepsy, is classified as a Schedule III controlled substance in the US, allowing limited medical use. It is similarly regulated in many countries due to its potential for abuse. The UNODC and other regulatory bodies emphasize the need for balanced regulation to ensure safe medical use while preventing misuse.
US Federal Schedule - III
Schedule III drugs, substances, or chemicals are defined as drugs with a moderate to low potential for physical and psychological dependence. Schedule III drugs abuse potential is less than Schedule I and Schedule II drugs but more than Schedule IV. Some examples of Schedule III drugs are: products containing less than 90 milligrams of codeine per dosage unit (Tylenol with codeine), ketamine, anabolic steroids, testosterone.
Key US Federal Policies:
Controlled Substances Act. Public Law: Public Law 91-513 (text can be found on GovInfo) (https://www.dea.gov/drug-information/csa). Date enacted: October 27, 1970.
|
|
VI. Physical Effects
Perampanel is an anticonvulsant used for epilepsy, affecting neurotransmitter activity. It can cause dizziness, drowsiness, and changes in heart rate. Short-term use is effective for seizure control, while long-term use may lead to mood changes and cognitive effects. Overdose risks include severe drowsiness and possible behavioral disturbances. Safe dosing is typically guided by a healthcare provider. Recent research focuses on its efficacy in seizure management and side effects.  |
|
VII. Psychological Effects
Perampanel, an AMPA receptor antagonist, is used to treat epilepsy. It can cause dizziness, irritability, and aggression. Immediate effects include mood changes and potential euphoria. Long-term use may lead to behavioral changes, cognitive impairment, and depression. Recent research indicates its impact on mood and aggression, necessitating careful monitoring in patients.
 |
|
VIII. Culture
Perampanel is an antiepileptic drug used to treat seizures in patients with epilepsy. Its cultural significance is tied to advancements in the treatment of neurological disorders and the improvement in quality of life for individuals with epilepsy. Historically, epilepsy has been misunderstood and stigmatized, but modern medications like perampanel represent progress in managing the condition. Perampanel's development highlights the importance of continued research and innovation in neurological therapeutics. Media coverage often emphasizes the impact of such drugs on patient outcomes and the ongoing challenges in developing effective treatments for epilepsy and other neurological disorders.
 |